{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:23:38Z","timestamp":1790774618818,"version":"4.1.0"},"reference-count":52,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A27894"],"award-info":[{"award-number":["A27894"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","award":["RIA16-ST2-022"],"award-info":[{"award-number":["RIA16-ST2-022"]}],"id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,7,10]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Androgen deprivation therapy (ADT) is a front-line treatment for prostate cancer. In some men, their tumors can become refractory leading to the development of castration-resistant prostate cancer (CRPC). This causes tumors to regrow and metastasize, despite ongoing treatment, and impacts negatively on patient survival. ADT is known to stimulate the accumulation of immunosuppressive cells like protumoral tumor-associated macrophages (TAMs), myeloid-derived suppressor cells and regulatory T cells in prostate tumors, as well as hypofunctional T cells. Protumoral TAMs have been shown to accumulate around tumor blood vessels during chemotherapy and radiotherapy in other forms of cancer, where they drive tumor relapse. Our aim was to see whether such perivascular (PV) TAMs also accumulate in ADT-treated prostate tumors prior to CRPC, and, if so, whether selectively inducing them to express a potent immunostimulant, interferon beta (IFN\u03b2), would stimulate antitumor immunity and delay CRPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used multiplex immunofluorescence to assess the effects of ADT on the distribution and activation status of TAMs, CD8+T cells, CD4+T cells and NK cells in mouse and\/or human prostate tumors. We then used antibody-coated, lipid nanoparticles (LNPs) to selectively target a STING agonist, 2\u20323\u2032-cGAMP (cGAMP), to PV TAMs in mouse prostate tumors during ADT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TAMs accumulated at high density around blood vessels in response to ADT and expressed markers of a protumoral phenotype including folate receptor-beta (FR-\u03b2), MRC1 (CD206), CD169 and VISTA. Additionally, higher numbers of inactive (PD-1-) CD8+T cells and reduced numbers of active (CD69+) NK cells were present in these PV tumor areas. LNPs coated with an antibody to FR-\u03b2 selectively delivered cGAMP to PV TAMs in ADT-treated tumors, where they activated STING and upregulated the expression of IFN\u03b2. This resulted in a marked increase in the density of active CD8+T cells (along with CD4+T cells and NK cells) in PV tumor areas, and significantly delayed the onset of CRPC. Antibody depletion of CD8+T cells during LNP administration demonstrated the essential role of these cells in delay in CRPC induced by LNPs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Together, our data indicate that targeting a STING agonist to PV TAMs could be used to extend the treatment window for ADT in prostate cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-009368","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T01:41:54Z","timestamp":1721958114000},"page":"e009368","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy"],"prefix":"10.1136","volume":"12","author":[{"given":"Haider","family":"Al-janabi","sequence":"first","affiliation":[{"name":"Divsion of Clinical Medicine, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Moyes","sequence":"additional","affiliation":[{"name":"Divsion of Clinical Medicine, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Allen","sequence":"additional","affiliation":[{"name":"Divsion of Clinical Medicine, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Fisher","sequence":"additional","affiliation":[{"name":"Divsion of Clinical Medicine, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateus","family":"Crespo","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Gurel","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Rescigno","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Nunns","sequence":"additional","affiliation":[{"name":"NeoGenomics Laboratories Inc Aliso Viejo, Aliso Viejo, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bailey","sequence":"additional","affiliation":[{"name":"Lipexogen Biotech, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Junker-Jensen","sequence":"additional","affiliation":[{"name":"NeoGenomics Laboratories Inc Aliso Viejo, Aliso Viejo, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munitta","family":"Muthana","sequence":"additional","affiliation":[{"name":"Division of Clinical Medicine, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7961-638X","authenticated-orcid":false,"given":"Wayne A","family":"Phillips","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen B","family":"Pearson","sequence":"additional","affiliation":[{"name":"Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Ellen","family":"Taplin","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E","family":"Brown","sequence":"additional","affiliation":[{"name":"Division of Clinical Medicine, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1938-9530","authenticated-orcid":false,"given":"Claire E","family":"Lewis","sequence":"additional","affiliation":[{"name":"Divsion of Clinical Medicine, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"2025100313573808000_12.7.e009368.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.06.006"},{"key":"2025100313573808000_12.7.e009368.2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8123"},{"key":"2025100313573808000_12.7.e009368.3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-319-99286-0_7","article-title":"Castration-resistant prostate cancer: mechanisms, targets and treatment","volume":"1096","author":"Mansinho","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"2025100313573808000_12.7.e009368.4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2017.08.009","article-title":"Targeting androgen-independent pathways: new chances for patients with prostate cancer?","volume":"118","author":"Cattrini","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025100313573808000_12.7.e009368.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-017-0013-x"},{"key":"2025100313573808000_12.7.e009368.6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3372"},{"key":"2025100313573808000_12.7.e009368.7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.251140998"},{"key":"2025100313573808000_12.7.e009368.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2009.06.004"},{"key":"2025100313573808000_12.7.e009368.9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5659","article-title":"Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse","volume":"8","author":"Pu","year":"2016","journal-title":"Sci Transl Med"},{"key":"2025100313573808000_12.7.e009368.10","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.878353","article-title":"Influence of androgen deprivation therapy on the PD-L1 expression and immune activity in prostate cancer tissue","volume":"9","author":"Sommer","year":"2022","journal-title":"Front Mol Biosci"},{"key":"2025100313573808000_12.7.e009368.11","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1055826","article-title":"Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer","volume":"13","author":"Qin","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025100313573808000_12.7.e009368.12","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2499"},{"key":"2025100313573808000_12.7.e009368.13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9020013","article-title":"Immune modulation by androgen deprivation and radiation therapy: implications for prostate cancer immunotherapy","volume":"9","author":"Kalina","year":"2017","journal-title":"Cancers (Basel)"},{"key":"2025100313573808000_12.7.e009368.14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0992"},{"key":"2025100313573808000_12.7.e009368.15","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.3390\/cancers13112695","article-title":"STING agonists as cancer therapeutics","volume":"13","author":"Amouzegar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025100313573808000_12.7.e009368.16","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01361-0"},{"key":"2025100313573808000_12.7.e009368.17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115596","article-title":"Strategies involving STING pathway activation for cancer immunotherapy: mechanism and agonists","volume":"213","author":"Pan","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"2025100313573808000_12.7.e009368.18","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27144638","article-title":"Activation of stimulation of interferon genes (STING) signal and cancer immunotherapy","volume":"27","author":"Luo","year":"2022","journal-title":"Molecules"},{"key":"2025100313573808000_12.7.e009368.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2019.01.013"},{"key":"2025100313573808000_12.7.e009368.20","article-title":"Type I interferons and natural killer cell regulation in cancer","volume":"8","author":"M\u00fcller","year":"2013","journal-title":"Front Immunol"},{"key":"2025100313573808000_12.7.e009368.21","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.3390\/jcm9103323","article-title":"Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy","volume":"9","author":"Motedayen Aval","year":"2020","journal-title":"JCM"},{"key":"2025100313573808000_12.7.e009368.22","doi-asserted-by":"crossref","DOI":"10.1016\/j.mtbio.2023.100839","article-title":"Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: a comprehensive review of strategies and future perspectives","volume":"23","author":"Huang","year":"2023","journal-title":"Mater Today Bio"},{"key":"2025100313573808000_12.7.e009368.23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3441"},{"key":"2025100313573808000_12.7.e009368.24","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/2159-8290.CD-17-0867","article-title":"Identification of pik3ca mutation as a genetic driver of prostate cancer that cooperates with pten loss to accelerate progression and castration-resistant growth","volume":"8","author":"Pearson","year":"2020","journal-title":"Cancer Discov"},{"key":"2025100313573808000_12.7.e009368.25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1291643","article-title":"Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse","volume":"14","author":"Moamin","year":"2023","journal-title":"Front Immunol"},{"key":"2025100313573808000_12.7.e009368.26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121741","article-title":"A robust post-insertion method for the preparation of targeted sirna lnps","volume":"620","author":"Swart","year":"2022","journal-title":"Int J Pharm"},{"key":"2025100313573808000_12.7.e009368.27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cell.2020.08.040","article-title":"Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma","volume":"183","author":"Sharma","year":"2020","journal-title":"Cell"},{"key":"2025100313573808000_12.7.e009368.28","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106012","article-title":"Breast cancer cells promote CD169+ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages","volume":"78","author":"Jing","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2025100313573808000_12.7.e009368.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.12.008"},{"key":"2025100313573808000_12.7.e009368.30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.566511","article-title":"Tumor-associated macrophages in human breast, colorectal, lung, ovarian and prostate cancers","volume":"10","author":"Larionova","year":"2020","journal-title":"Front Oncol"},{"key":"2025100313573808000_12.7.e009368.31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3587"},{"key":"2025100313573808000_12.7.e009368.32","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2033210"},{"key":"2025100313573808000_12.7.e009368.33","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.devcel.2023.06.006","article-title":"LYVE-1+ macrophages form a collaborative CCR5-dependent perivascular niche that influences chemotherapy responses in murine breast cancer","volume":"58","author":"Anstee","year":"2023","journal-title":"Dev Cell"},{"key":"2025100313573808000_12.7.e009368.34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002802"},{"key":"2025100313573808000_12.7.e009368.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101399","article-title":"A multiomics analysis-assisted deep learning model identifies a macrophage-oriented module as a potential therapeutic target in colorectal cancer","volume":"5","author":"Bao","year":"2024","journal-title":"Cell Rep Med"},{"key":"2025100313573808000_12.7.e009368.36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-20893-2","article-title":"CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy","volume":"12","author":"Rodriguez-Garcia","year":"2021","journal-title":"Nat Commun"},{"key":"2025100313573808000_12.7.e009368.37","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic ph-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature New Biol"},{"key":"2025100313573808000_12.7.e009368.38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1605885113"},{"key":"2025100313573808000_12.7.e009368.39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.726492","article-title":"Multi-parameter quantitative imaging of tumor microenvironments reveals perivascular immune niches associated with anti-tumor immunity","volume":"12","author":"Stoltzfus","year":"2021","journal-title":"Front Immunol"},{"key":"2025100313573808000_12.7.e009368.40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1180209","article-title":"Breast cancer associated CD169+ macrophages possess broad immunosuppressive functions but enhance antibody secretion by activated B cells","volume":"14","author":"Gunnarsdottir","year":"2023","journal-title":"Front Immunol"},{"key":"2025100313573808000_12.7.e009368.41","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221007","article-title":"Macrophages promote anti-androgen resistance in prostate cancer bone disease","volume":"220","author":"Li","year":"2023","journal-title":"J Exp Med"},{"key":"2025100313573808000_12.7.e009368.42","doi-asserted-by":"crossref","first-page":"496","DOI":"10.4049\/jimmunol.2200696","article-title":"Restored thymic output after androgen blockade participates in antitumor immunity","volume":"210","author":"Polesso","year":"2023","journal-title":"J Immunol"},{"key":"2025100313573808000_12.7.e009368.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2012.07.008"},{"key":"2025100313573808000_12.7.e009368.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2010.02.007"},{"key":"2025100313573808000_12.7.e009368.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.07.005"},{"key":"2025100313573808000_12.7.e009368.46","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050821"},{"key":"2025100313573808000_12.7.e009368.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0011-2"},{"key":"2025100313573808000_12.7.e009368.48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062366","article-title":"Interferon-beta induces distinct gene expression response patterns in human monocytes versus T cells","volume":"8","author":"Henig","year":"2013","journal-title":"PLoS One"},{"key":"2025100313573808000_12.7.e009368.49","doi-asserted-by":"publisher","DOI":"10.1159\/000097977"},{"key":"2025100313573808000_12.7.e009368.50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0502188102"},{"key":"2025100313573808000_12.7.e009368.51","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12041446","article-title":"Immunotherapy for prostate cancer: a current systematic review and patient centric perspectives","volume":"12","author":"Rehman","year":"2023","journal-title":"J Clin Med"},{"key":"2025100313573808000_12.7.e009368.52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbrc.2006.05.081","article-title":"Functional expression of human type I interferon receptors in the mouse liver","volume":"346","author":"Tochizawa","year":"2006","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:57:45Z","timestamp":1759525065000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":52,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,25]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/jitc-2024-009368"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009368","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.04.11.589003","asserted-by":"object"}]},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}